Larimar Q2 2026: $156.3M Cash, Rolling BLA Underway, Phase 3 Start Imminent
LRMR sits 40% above its 52-week low of $2.715 on light trading volume (0.4× avg).
Summary
Larimar Therapeutics posted Q2 2026 financials with $156.3M in cash, shared updated open-label data showing sustained frataxin increases and clinical improvements, and confirmed the rolling BLA submission is underway with completion expected in 2H 2026. Dosing of the first patient in the global Phase 3 confirmatory study is anticipated in Q3 2026.
Key Events · Earnings and Guidance · LRMR
-
Q2 2026 Financial Results
A net loss of $32.8M ($0.30/share) compared with $26.2M ($0.41/share) in Q2 2025. Cash, cash equivalents, and marketable securities stood at $156.3M as of June 30, 2026, providing a projected runway into Q3 2027.
-
Rolling BLA Submission Progress
The first module of the rolling BLA for nomlabofusp was submitted in June 2026, with the remaining modules expected in 2H 2026. The FDA has aligned on using FXN as a novel surrogate endpoint and confirmed the existing data package is sufficient for accelerated approval.
-
Updated Open-Label Study Data
As of June 2026, 43 participants have been dosed, with sustained skin FXN increases: 100% (9/9) at 1 year and 100% (3/3) at 18 months reached levels comparable to asymptomatic carriers. A 2.6-point mFARS benefit versus the FACOMS reference group was observed at 1 year, widening to a 4.6-point benefit at 18 months. The safety profile remains well-characterized, though 10 cases of anaphylaxis were reported (9 with prior exposure).
-
Phase 3 Confirmatory Study Initiation
A global double-blind, placebo-controlled Phase 3 study is expected to dose its first patient in Q3 2026. It will enroll 100–150 ambulatory participants aged 2–40 years, with upright stability (U.S.) and mFARS (EU) as primary endpoints.
Analysis · LRMR · Life Sciences
The Q2 update strengthens the nomlabofusp thesis: a cash runway into Q3 2027, a rolling BLA already in motion, and a confirmatory Phase 3 trial set to dose its first patient this quarter. Open-label data continue to show sustained frataxin increases and a 2.6-point mFARS benefit at one year, supporting the accelerated approval path. With $156.3 million on hand and a mid-2027 launch target, the company is fully funded through key catalysts, though the anaphylaxis cases in the open-label study remain a safety overhang that the FDA will scrutinize.
At the time of this filing, LRMR was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $413.5M. The 52-week trading range was $2.72 to $6.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.